| Active Not Recruiting | Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas NCT07448480 | Blokhin's Russian Cancer Research Center | — |
| Recruiting | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion NCT06333899 | Nationwide Children's Hospital | EARLY_Phase 1 |
| Recruiting | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age NCT05956821 | University of Miami | Phase 1 / Phase 2 |
| Recruiting | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant NCT05843253 | Nationwide Children's Hospital | Phase 2 |
| Recruiting | Targeted Pediatric High-Grade Glioma Therapy NCT05839379 | Nationwide Children's Hospital | — |
| Recruiting | DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glio NCT06264388 | Ashish Shah | Phase 2 |
| Unknown | Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas NCT06241391 | All India Institute of Medical Sciences, Bhubaneswar | N/A |
| Recruiting | Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma NCT06108206 | Columbia University | N/A |
| Suspended | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumo NCT05934630 | Pediatric Brain Tumor Consortium | — |
| Recruiting | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma NCT05698524 | University of Nebraska | Phase 1 |
| Active Not Recruiting | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma an NCT04978727 | Children's Oncology Group | Phase 1 |
| Recruiting | Study of Pembrolizumab and M032 (NSC 733972) NCT05084430 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Terminated | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection NCT04608812 | OncoSynergy, Inc. | Phase 1 |
| Recruiting | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082 | Jazz Pharmaceuticals | Phase 1 |
| Completed | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas NCT04295759 | Pediatric Brain Tumor Consortium | Phase 1 |
| Active Not Recruiting | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Gra NCT03919071 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolom NCT04105374 | NRG Oncology | Phase 2 / Phase 3 |
| Terminated | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in P NCT03971734 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Active Not Recruiting | Pediatric Long-Term Follow-up and Rollover Study NCT03975829 | Novartis Pharmaceuticals | Phase 4 |
| Terminated | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG NCT03973918 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma With NCT03581292 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | 3D Prediction of Patient-Specific Response NCT03561207 | KIYATEC | — |
| Completed | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies fo NCT03434262 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM NCT03603405 | The Methodist Hospital Research Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant NCT03180502 | NRG Oncology | Phase 2 |
| Completed | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 NCT02684058 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | Loupe-Based Intraoperative Fluorescence Imaging NCT04780009 | Guoqiang Yu | — |
| Completed | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied NCT03355794 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Completed | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children NCT03043391 | Istari Oncology, Inc. | Phase 1 |
| Terminated | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 NCT03332355 | Vanquish Oncology, Inc. | Phase 1 |
| Terminated | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children NCT02885324 | Indiana University | Phase 2 |
| Completed | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma NCT03072134 | Northwestern University | Phase 1 |
| Completed | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma NCT02101905 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy NCT03370926 | University Hospital, Brest | — |
| Unknown | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients NCT02796261 | Orbus Therapeutics, Inc. | Phase 3 |
| Recruiting | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Re NCT02800486 | Northwell Health | Phase 2 |
| Completed | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors NCT02644291 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain NCT02457845 | Gregory K. Friedman, MD | Phase 1 |
| Terminated | Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Gliom NCT02758366 | Meyer Children's Hospital IRCCS | Phase 2 |
| Terminated | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma NCT02414165 | Tocagen Inc. | Phase 2 / Phase 3 |
| Terminated | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance De NCT02372409 | Washington University School of Medicine | Phase 2 |
| Completed | A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma NCT02490930 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Unknown | A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas NCT02629757 | Sun Yat-sen University | Phase 3 |
| Withdrawn | Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma NCT02540135 | University of Colorado, Denver | N/A |
| Completed | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas NCT02238496 | Andrew B Lassman, MD | Phase 1 |
| Terminated | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma NCT02168270 | University of Nebraska | Phase 1 |
| Completed | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brai NCT01985256 | Tocagen Inc. | Phase 1 |
| Completed | Phase I Study of Safety and Immunogenicity of ADU-623 NCT01967758 | Providence Health & Services | Phase 1 |
| Completed | Immunophenotyping From Blood of Patients With Malignant Gliomas NCT02022384 | University of Erlangen-Nürnberg Medical School | — |
| Terminated | Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma NCT02039778 | Beth Israel Medical Center | N/A |
| Completed | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas NCT01837862 | Julie Krystal | Phase 1 / Phase 2 |
| Terminated | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas NCT01849952 | Dartmouth-Hitchcock Medical Center | — |
| Completed | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gl NCT01922076 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma NCT01808820 | Macarena De La Fuente, MD | Phase 1 |
| Completed | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors NCT01975116 | Pediatric Brain Tumor Consortium | Phase 1 |
| Terminated | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Unde NCT01884740 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Withdrawn | Valproic Acid in Childhood Progressive Brain Tumors NCT01861990 | Medical University of South Carolina | Phase 1 |
| Terminated | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors NCT01836549 | Pediatric Brain Tumor Consortium | Phase 2 |
| Withdrawn | Re-irradiation of High Grade Gliomas: a Quality of Life Study NCT01711580 | Maastricht Radiation Oncology | — |
| Terminated | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas NCT01721577 | Rush University Medical Center | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma NCT01250470 | Roswell Park Cancer Institute | Phase 1 |
| Unknown | A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Glio NCT01765088 | Sun Yat-sen University | Phase 3 |
| Unknown | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma NCT01656980 | Shandong Lanjin Pharmaceuticals Co.,Ltd | Phase 3 |
| Unknown | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma NCT01637753 | Shandong Lanjin Pharmaceuticals Co.,Ltd | N/A |
| Completed | BIBF 1120 for Recurrent High-Grade Gliomas NCT01380782 | Patrick Y. Wen, MD | Phase 2 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Quality of Life and Patient Needs in Advanced High Grade Gliomas NCT05039346 | Henry Ford Health System | — |
| Completed | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Re NCT01470794 | Tocagen Inc. | Phase 1 |
| Completed | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Ponti NCT01514201 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Suspended | Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Rela NCT01386710 | Northwell Health | Phase 1 / Phase 2 |
| Completed | AZD8055 for Adults With Recurrent Gliomas NCT01316809 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas NCT01281982 | National Cancer Institute (NCI) | — |
| Completed | Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas NCT01222754 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dendritic Cell Vaccine for Patients With Brain Tumors NCT01204684 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GB NCT01269853 | Northwell Health | Phase 1 / Phase 2 |
| Terminated | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma NCT01227434 | University of California, San Francisco | Phase 2 |
| Completed | Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor NCT01171469 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients NCT01189266 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM NCT01180816 | Northwell Health | Phase 1 |
| Completed | Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Bra NCT01151670 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Cellular Immunotherapy Study for Brain Cancer NCT01144247 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Mal NCT01156584 | Tocagen Inc. | Phase 1 |
| Completed | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions NCT01082926 | City of Hope Medical Center | Phase 1 |
| Completed | Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GB NCT01238237 | Northwell Health | Phase 1 |
| Completed | Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Gli NCT00879437 | Baylor College of Medicine | Phase 2 |
| Completed | A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Fo NCT00995007 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) NCT00968240 | Northwell Health | Phase 1 |
| Withdrawn | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma NCT00734864 | Annick Desjardins | Phase 1 |
| Completed | Sorafenib in Newly Diagnosed High Grade Glioma NCT00884416 | University Hospital, Geneva | Phase 1 |
| Terminated | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma NCT01095094 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary G NCT00761280 | Isarna Therapeutics GmbH | Phase 3 |
| Completed | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas NCT00734682 | University of California, San Francisco | Phase 1 |
| Completed | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors NCT00667394 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patien NCT00645385 | Weill Medical College of Cornell University | — |
| Terminated | The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astroc NCT00473408 | Haukeland University Hospital | — |
| Completed | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma NCT00589875 | Candel Therapeutics, Inc. | Phase 2 |
| Completed | A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma NCT00606008 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using NCT00409214 | Light Sciences Oncology | Phase 2 |
| Completed | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme NCT00390299 | Mayo Clinic | Phase 1 |
| Completed | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma NCT00301418 | Northwell Health | Phase 1 / Phase 2 |
| Completed | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas NCT00751270 | Candel Therapeutics, Inc. | Phase 1 |
| Completed | PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas NCT00612651 | Duke University | Phase 1 |
| Completed | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas NCT00100802 | Children's Oncology Group | Phase 2 |
| Completed | Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly NCT01502241 | Heidelberg University | Phase 3 |
| Unknown | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma NCT00114309 | TransMolecular | Phase 2 |
| Completed | IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Pat NCT00089427 | INSYS Therapeutics Inc | Phase 1 |
| Completed | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas NCT00610571 | Katy Peters | Phase 1 |
| Terminated | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas NCT00062504 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Completed | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recu NCT00064779 | INSYS Therapeutics Inc | Phase 1 |
| Completed | Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma NCT00431561 | Isarna Therapeutics GmbH | Phase 2 |
| Completed | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma NCT00041587 | INSYS Therapeutics Inc | Phase 1 / Phase 2 |
| Terminated | Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) NCT00035373 | National Cancer Institute (NCI) | — |
| Completed | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade NCT00031083 | Biogen | Phase 1 |
| Terminated | Genetic Analysis of Brain Tumors NCT00031538 | National Cancer Institute (NCI) | — |
| Completed | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant G NCT00024557 | INSYS Therapeutics Inc | Phase 1 |
| Completed | BNCT to Treat Glioma That Has Progressed Following Radiotherapy NCT00115440 | Boneca Corporation | Phase 1 / Phase 2 |
| Completed | Radiotherapy for Malignant Astrocytomas in the Elderly NCT00430911 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma NCT00024570 | INSYS Therapeutics Inc | Phase 1 / Phase 2 |
| Completed | Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide NCT00717210 | Neuro-Oncology Working Group of the German Cancer Society | Phase 3 |
| Completed | Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms NCT00004688 | Emory University | Phase 2 |
| Completed | Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma NCT00003470 | Burzynski Research Institute | Phase 2 |
| No Longer Available | Expanded Access to ANG1005 for Individual Patients NCT02755987 | Angiochem Inc | — |